Estudo randomizado | Seguimento pós-parto de 72 semanas de dolutegravir vs. efavirenz iniciado na gestação.

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study – The Lancet HIV

Conteúdos relacionados:

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1